ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
The Current Advances in Design Strategy (Indirect Strategy and Direct Strategy) for Type-I Photosensitizers.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Metal-Based Photosensitizers as Emerging Antibacterial Agents for Infected Wound Healing.ChemMedChem · 2026Review
- Spin trap-mediated conversion of singlet oxygen to hydroxyl radical in photosensitization: mechanistic insights and the role of biological reductants.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026Article
- A Planarity-Hindrance Co-Balance Strategy to Develop Antiparallel H-Aggregates With Minimal Absorbance Blueshift for Type I Photodynamic Therapy.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Unlocking Phthalonitrile-Based Type I Photosensitizer Through D-A Modulation to Promote Electron Transfer.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Acceptor Engineering-Mediated Charge-Transfer Control: A Hierarchical Framework for Predictive Design of High-Performance Type I AIE Photosensitizers.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Enhancing Tumor Photodynamic Therapy via Molecular Engineering and Functional Modification of Photosensitizers.Molecules (Basel, Switzerland) · 2026Review
- A Closed-Loop Hybrid Discovery System of Type I Photosensitizers for Hypoxic Tumor Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Engineering Carbon Nitride Quantum Dots via Sulfur Doping for Controlled Reactive Oxygen Species Generation.Global challenges (Hoboken, NJ) · 2026Article
- Oxygenation: Nanotechnological Strategies for Conquering Tumor Hypoxia in Photodynamic Therapy.International journal of nanomedicine · 2026Review
- Self-Assembled Cationic Phthalocyanine Nanophotosensitizer Drives Hypoxia-Tolerant Photodynamic Immunotherapy for HCC.International journal of nanomedicine · 2026Article
- Mitochondria-localized photocatalyst of biomimetic organic semiconductor nanoparticles for NIR-activatable photocatalytic immunotherapy.Science advances · 2025Article
- Multifunctional gold nanoclusters as next-generation theranostic platforms for disease management.International journal of pharmaceutics: X · 2025Review
- The Current Advances in Design Strategy (Indirect Strategy and Direct Strategy) for Type-I Photosensitizers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Type-I photosensitizers (PSs) are among the most potential candidates for photodynamic therapy (PDT), as their low dependence on oxygen endow them with many advantages for treating hypoxic tumor. However, most of the reported type-I PSs have a contingency of molecular design, because electron transfer (ET) reaction is more difficult to achieve than energy transfer (EET) process. Therefore, it is urgent to understand molecular design mechanisms for type-I PSs. In this review, the two ways to achieve the type-I PSs, i.e., inhibiting EET process (type-II) or enhancing ET process (type-I), are detailly explained. In response, the current design strategies of type-I PSs are summarized from two perspectives: indirect strategy (inhibiting EET process: reducing the energy of the lowest triplet excited state (T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.